Open Access

Circular RNAs in cancer: an emerging key player

  • Yeping Dong1,
  • Dan He1,
  • Zhenzi Peng1,
  • Wei Peng1,
  • Wenwen Shi1,
  • Jun Wang1,
  • Bin Li1,
  • Chunfang Zhang2 and
  • Chaojun Duan1, 2, 3Email author
Journal of Hematology & Oncology201710:2

https://doi.org/10.1186/s13045-016-0370-2

Received: 13 September 2016

Accepted: 6 December 2016

Published: 3 January 2017

Abstract

Circular RNAs (circRNAs) are a class of endogendous RNAs that form a covalently closed continuous loop and exist extensively in mammalian cells. Majority of circRNAs are conserved across species and often show tissue/developmental stage-specific expression. CircRNAs were first thought to be the result of splicing error; however, subsequent research shows that circRNAs can function as microRNA (miRNA) sponges and regulate splicing and transcription. Emerging evidence shows that circRNAs possess closely associated with human diseases, especially cancers, and may serve as better biomarkers. After miRNA and long noncoding RNA (lncRNA), circRNAs are becoming a new hotspot in the field of RNA of cancer. Here, we review biogenesis and metabolism of circRNAs, their functions, and potential roles in cancer.

Keywords

Circular RNAs Cancer MicroRNA sponges Biomarkers

Background

Noncoding RNAs (ncRNA) can be categorized into two subclasses, namely housekeeper ncRNAs (ribosomal RNA (rRNA), tRNA, small nuclear RNA (snRNA), snoRNA) and regulatory ncRNAs. Regulatory ncRNAs have been classified by length as follows: small noncoding RNAs (<200 bp), which includes microRNAs (miRNAs), snRNAs, piRNAs, siRNAs, and others, and long ncRNAs (lncRNAs) (>200 bp). Among the lncRNAs, circular RNAs (circRNAs) have recently emerged as a new class of endogenous RNAs that form a covalently closed continuous loop without 5′ caps and 3′ tails and exist extensively in mammalian cells. CircRNA was first found more than 20 years ago from identifying spliced transcripts of a candidate tumor suppressor gene by Nigro et al. in 1991 [1]. However, this novel type of RNA product has been thought to result from splicing errors with no function [2] and paid little attention over the next decade. Because of rapid advances in high-throughput sequencing, a large number of circRNAs have been discovered and several properties were uncovered. Firstly, circRNAs seem to be specifically expressed in tissues or developmental stage [3]. Secondly, circRNAs were more stable than associated linear mRNAs in vivo for their resistance to RNase activity [3, 4]. Thirdly, circRNAs from >14% of actively transcribed genes in human fibroblasts and in some cases the abundance of circular molecules exceeded that of associated linear mRNA by >10-fold [4]. Also, they are predominately cytoplasmic, but some seemed to be enriched in the nucleus [35].

Biogenesis of circRNAs

CircRNAs have multiple origins. The majority of them are originated from exons of coding regions and the rest from 3′ UTR, 5′ UTR, introns, intergenic regions, and antisense RNAs [6]. Different from canonical splicing of linear RNAs, a single gene locus can produce various circRNAs through alternative back-splice site selection [7]. CircRNAs can be generated by both canonical and noncanonical splicing (Fig. 1). Up to now, three types of circRNAs have been identified by high-throughput sequencing: exonic circRNAs [4], circular intronic RNAs (ciRNAs) [8], and retained-intron circRNAs or ElciRNAs [9]. Exonic circRNAs account for over 80% of identified circRNAs. However, the mechanisms of biogenesis of circRNAs remain unclear. In 2013, Jeck et al. proposed two models of exonic circRNA formation [4]. One model is named “lariat-driven circularization,” and the other one is named “intronpairing-driven circularization”. It is widely accepted that back-splicing occurs in reversed orientation that connects a downstream 5′ splice site to an upstream 3′ splice site to produce circRNAs [7]. Ivanov et al. reported that circRNA formation mechanism depends on the RNA-editing enzyme adenosine deaminase acting on RNA (ADAR) [10]. Additionally, researchers reported that the RNA-binding quaking (QKI) could facilitate circRNA biogenesis during epithelial to mesenchymal transition (EMT) [11]. Recently, Gao et al. explored internal components including alternative splicing events (AS) such as exon skipping (ES), intron retention (IR), and alternative 5′ or 3′ splicing site (A5SS and A3SS) within circRNAs [12]. They demonstrated that frequency of AS events varies in different cell types, which suggest their potential roles in gene regulation.
Fig. 1

Canonical and noncanonical splicing of circRNA. a mRNA and ciRNA by canonical splicing. b circRNA by direct back splicing. c ciRNA by back splicing. d circRNA and EIciRNA by RBP-driven circularization. Abbreviations: ciRNA circular intronic RNA, circRNA exonic circular RNA, ElciRNA exon-intron circular RNA, RBP RNA-binding protein

Biological functions of circRNAs

CircRNAs can function as miRNA sponges, RNA-binding protein (RBP) sponges, and regulators of transcription, and few circRNAs can be translated into proteins/peptides (Fig. 2).
Fig. 2

Overview of the four molecular functions of circRNA. a circRNAs can interact with miRNAs, acting as “sponges”. b circRNA have a direct role in translation. c ciRNA can enhance the expression of parent genes; ElciRNA can also enhance the expression of parental genes with U1 snRNP and Pol II. d circRNA can generate functional proteins. Abbreviations: circRNAs circular RNAs, miRNA microRNA, ciRNA circular intronic RNA, Pol II polymerase II, ElciRNA exon-intron circular RNA, U1 snRNP U1 small nuclear ribonucleoprotein particle, mRNA messenger RNA, rRNA ribosome RNA

miRNA sponge

MiRNAs are an abundant class of short (~22 nt) noncoding RNAs that posttranscriptionally regulate gene expression via direct base pairing to target sites within mRNAs [13]. As the competitive endogenous RNAs (ceRNAs), circRNAs can compete for miRNA-binding sites. Thus, the presence of miRNAs sponges, circRNAs, can affect miRNA activities [3, 14]. For example, a circRNA named ciRS-7 or CDR1as (circular RNA sponge for miR-7 or antisense to the cerebellar degeneration-related protein 1 transcript) contains more than 70 selectively conserved miRNA target sites, and it is highly associated with Argonaute (AGO) proteins in a miR-7-dependent manner [14].

Regulators of transcription

Previous studies have provided evidence that circRNAs form a large number of posttranscriptional regulators [3]. Zhang and colleagues uncovered that circRNAs could regulate the expression of parental genes. They discovered that circRNAs are abundant in the nucleus with little enrichment for miRNA target sites, and knockdown of ciRNAs could lead to the reduced expression of their parental genes [3, 8]. Moreover, researchers reported after further studies that ElciRNAs, such as circEIF3J and circPAIP2, interact with U1 small nuclear ribonucleoprotein particle (U1snRNP) RNA and polymerase II (Pol II) and can enhance the transcription of their parental genes in a cis-acting manner [15]. The similar trend was also observed in circRNA PAIP2 and its parental gene [16].

From the above, we speculate that transcription activation may be a general function of circular RNAs containing intronic sequences, such as ciRNAs and EIciRNAs, and their regulatory functions may explain the abundance of ciRNAs and EIciRNAs in the nucleus.

Translation of circRNAs into protein/peptide

As some circRNAs carry open reading frames, one may speculate that they are translated into peptides. Early in 1998, Perriman et al. reported that a circular mRNA containing a simple green fluorescent protein (GFP) open reading frame could direct GFP expression in Escherichia coli [16]. Subsequently, AbouHaidar et al. discovered a circRNA (220 nt) of the virusoid associated with rice yellow mottle virus can code for a 16-kD protein [17]. It was shown that peptides can be translated from circRNAs in vitro [18] or in vivo [16], only when the RNAs contain internal ribosome entry site elements (IRES) [18] or prokaryotic ribosome-binding sites [16]. Recently, a circRNA database, named circRNADb, containing 32,914 human exonic circRNAs was established [19]. It provided detailed information of the circRNAs, including genome sequence, IRES, and open reading frame (ORF), for users to predict the translatability of certain circRNAs. However, there is no experimental evidence to prove that spliceosome-generated ecircRNAs can serve as mRNAs.

Besides serving as miRNA sponge and transcription regulator, circRNAs certainly serve as mRNA traps via sequestering the translation start site to regulate protein expression [20].

Metabolism of circRNAs

CircRNAs are highly stable although the mechanisms by which cells degrade and/or clear circRNAs are unknown. Recently, researchers raised the possibility that cells can eliminate circRNAs via released vesicles such as exosomes and microvesicles when they reported secretion of multiple circRNAs from three different cell lines [21]. The result showed that circRNAs examined are enriched over their linear counterparts within extracellular vesicle (EV) preparations when compared to the producing cells, which suggests that expulsion from cells into extracellular space by EV release can be a mechanism by which cells reduce circRNAs.

CircRNAs in cancer

Emerging evidence shows that circRNAs possess closely associated with human diseases, especially cancers. A report revealed that hundreds of circRNAs are more abundant in blood than corresponding linear mRNAs, which suggests that circRNAs could be used as new biomarkers in standard clinical blood samples [22]. Here, we discuss recent discoveries that implicate aberrant circRNAs in cancer (Table 1).
Table 1

Summary of circRNAs in cancer

Cancer name

CircRNA name

Expression level

Scope

Sample

Intersection molecules and/or pathway

References

Bladder carcinoma

circTCF25

Up

Bladder carcinoma vs normal

Tissues (n = 40)

miR-103a-3p,miR-107; circTCF25-miR-103a-3p/miR-107-CDK6

Zhong et al. [28]

cSCC

hsa_circ_0035381

Up

cSCC vs normal

Tissues (n = 12)

hsa-miR-124-5p,hsa-miR-9-5p

Sand et al. [32]

hsa_circ_0022383

Down

hsa-miR-124-5p

ESCC

cir-ITCH

Down

ESCC vs normal

Tissues (n = 684)

miR-7, miR-17, and miR-214;Wnt/β-catenin pathway

Li et al. [34]

Gastric cancer

has_circ_002059

Down

Gastric cancer vs normal

Tissues (n = 101)

Li et al. [23]

Plasma (n = 36)

CRC

hsa_circ_001988

Down

CRC vs normal

Tissues (n = 31)

Wang et al. [24]

cir-ITCH

Down

CRC vs normal

Tissues (n = 45)

Wnt/β-catenin pathway

Huang et al. [25]

HCC

hsa_circ_0001649

Down

HCC vs normal

Tissues (n = 89)

Qin et al. [26]

LSCC

hsa_circ_104912

Down

LSCC vs normal

Tissues (n = 52)

Xuan et al. [27]

hsa_circ_100855

Up

APL

f-circRNA

f-circRNA-expressing vas normal

Cells

PI3K and MAPK signal transduction pathways

Guarnerio et al. [29]

Notes: Up upregulated, down downregulated

Abbreviations: circRNAs circular RNAs, cSCC cutaneous squamous cell carcinoma, ESCC esophageal squamous cell carcinoma, CRC colorectal cancer, HCC hepatocellular carcinoma, LSCC laryngeal squamous cell cancer, APL acute promyelocytic leukemia

CircRNAs and gastric cancer

A report showed that hsa_circ_002059, a typical circular RNA, was found to be significantly downregulated in gastric cancer tissues compared with paired adjacent nontumor tissues. Furthermore, its levels in plasma were found significantly different between postoperative gastric cancer patients and preoperative gastric cancer patients. Importantly, that lower expression levels were significantly correlated with distal metastasis, tumor node metastasis (TNM) stage, gender, and age. In conclusion, these results suggested that circRNAs, hsa_circ_002059, may be a potential stable biomarker for the diagnosis of gastric carcinoma [23].

This study clearly demonstrated the clinical implications of hsa_circ_002059 as a biomarker, since its expression is able to distinguish normal gastric adjacent mucosa from gastric cancer tissue. Further, this circRNA may also be used as a molecular biomarker in evaluating the effectiveness of gastric resection.

CircRNAs and colorectal cancer

Wang et al. investigated the circRNA expression in colorectal cancer (CRC), hsa_circ_001988, was selected from next-generation sequence data base for further investigation. The findings showed that the expression of hsa_circ_001988 was decreased in tumor tissues, which suggests that hsa_circ_001988 may be a novel treatment target and a potential biomarker of colorectal cancer [24].

Another report demonstrated that circRNAs were enriched in serum exosomes and could distinguish CRC from healthy controls [6]. Additionally, the abundance of tumor-derived serum exosomal circRNAs (exo-circRNAs) in serum of xenografted mice was correlated with tumor mass, which indicates that the exo-circRNAs may have an extracellular function and significant translational potential as a circulating biomarker for cancer diagnosis. Furthermore, it is also found that cir-ITCH expression was typically downregulated in CRC, and cir-ITCH could increase the level of ITCH, which is involved in the inhibition of the Wnt/β-catenin pathway. Thus, cir-ITCH may play a role in CRC by regulating the Wnt/β-catenin pathway [25]. Studies cited above illustrate that circRNAs are promising biomarkers for CRC.

CircRNAs and hepatocellular carcinoma

Hsa_circ_0001649 expression was significantly downregulated in hepatocellular carcinoma (HCC) tissues based on an analysis of 89 paired samples of HCC and adjacent liver tissues. The findings indicate that hsa_circ_0001649 might serve as a new potential biomarker for HCC and may play a role in tumorigenesis and metastasis of HCC [26].

CircRNAs and laryngeal cancer

Reseachers found significant upregulation (n = 302) or downregulation (n=396) of 698 circRNAs in laryngeal squamous cell cancer (LSCC) tissues via microarray analysis of four paired LSCC tissues. They further reported hsa_circRNA_100855 as the most upregulated circRNA, and their results showed that hsa_circRNA_100855 expression was significantly higher in LSCC than in the adjacent nonneoplastic tissues [27]. Overall, the data suggest that circRNAs play an important role in the tumorigenesis of LSCC and may function as novel and stable biomarkers for the diagnosis and progress of LSCC.

CircRNAs and bladder carcinoma

CircRNA profiling and circRNA/miRNA interactions were first studied in bladder cancer, and researchers demonstrated that overexpression of circTCF25 could downregulate miR-103a-3p and miR-107, increase cyclin-dependent kinase 6 (CDK6) expression, and promote proliferation and migration in vitro and in vivo. Their work laid the foundation to investigate the functions of circRNAs in cancers. The data also suggested that circTCF25 was a new promising marker for bladder cancer [28].

CircRNAs and acute promyelocytic leukemia

Researchers showed that well-established cancer-associated chromosomal translocations gave rise to fusion circRNAs (f-circRNA) that were produced from transcribed exons of distinct genes affected by the translocations. And then, they analyzed the presence of f-circRNA (both f-circPR and f-circM9) in the acute promyelocytic leukemia (APL)-derived leukemic cell line NB4. The data support the notion that f-circRNA, when coupled with other oncogenic stimuli, plays an active role in favoring leukemia progression in vivo [29]. Alhasan et al. found that circRNAs are enriched in human platelets 17- to 188-fold relative to nucleated tissues. As circRNAs are tolerated to degradation by exonucleases, their abundance relative to linear RNAs can be used as a marker in place of mRNA stability in the absence of transcription [30]. Previous research showed that mRNA sequencing of tumor-educated blood platelets could distinguish cancer patients from healthy population with 96% accuracy, and the location of the primary tumor was correctly identified with 71% accuracy across six different tumor types [31]. These results suggest that circRNAs and their quantity alteration in blood platelets may play a role in the diagnosis and treatment of tumor.

Other cancers

In a recent report, a total of 322 circRNAs were differentially expressed in cutaneous squamous cell carcinoma (cSCC) and 1603 miRNA response elements (MREs) were identified in the differentially expressed circRNAs. Results showed that circRNAs are differentially expressed in cSCC and are involved in tumor formation by interfering with cSCC relevant miRNAs via miRNA sequence complementary MREs participating in epigenetic control [32]. Another study explored that the circRNA expression signatures of PDAC are dysregulated via microarray platform. The findings indicate that circRNAs can be involved in the initiation and progression of PDAC [33]. Li et al. found that cir-ITCH expression was usually low in esophageal squamous cell carcinoma (ESCC) compared to the peritumoral tissue. As sponge of miR-7, miR-17, and miR-214, cir-ITCH might increase the level of ITCH, which hyper expression promotes ubiquitination and degradation of phosphorylated Dvl2, thereby inhibiting the Wnt/β-catenin pathway [34].

CDR1as contains more than 70 selectively conserved target sites of miR-7, and emerging evidence indicates that miR-7 can directly downregulate oncogenes. Thereby, the CDR1as/miRNA axis is likely involved in cancers such as melanoma [35], breast cancer [36], gliocytoma [37], gastric cancer [38], liver cancer [39], and non-small cell lung cancer (NSCLC) [40]. It would be interesting to uncover the function of CDR1as in cancer.

In summary, findings above indicate that circRNAs are potentially involved in cancer initiation and progression. Certain circRNAs, such as cir-ITCH, play roles in more than one type of cancers. However, most research cited above lack the clear demonstration of the molecular mechanism, and further insights into their association with cancer would be warranted. Thus, clinical implications of the circRNAs as new clinical diagnostic and prognostic markers need further studies.

Possible mechanisms of circRNAs in cancer

ceRNA

The competitive endogenous RNAs (ceRNAs) contain shared MREs, such as mRNAs, pseudogenes, and long noncoding RNAs (lncRNAs), and can compete for miRNA binding [41]. It is known that miRNAs have been shown to be involved in nearly all aspects of cellular functions [42] and play important roles in disease initiation and progression, especially in cancers [43, 44]. In view of circRNA-binding miRNAs to regulate their targets, circRNAs may be involved in various cancers with miRNAs. For example, CDR1as is known highly expressed and has over 60 binding sites for miR-7 [45]. Emerging evidence indicates that miR-7 can directly downregulate cancerigenic factors, including epidermal growth factor receptor (EGFR) [46], P21-activated kinase-1 (Pak1) [47], insulin receptor substrate-1 (IRS-1) [48], phosphoinositide 3-kinase catalytic subunit delta (PIK3CD) [49], and mammalian target of rapamycin (mTOR) [35]. Thereby, the CDR1as/miRNA axis is likely involved in many kinds of cancers. Recently, the first study to exploit circRNA profiling and circRNA/miRNA interactions in bladder cancer was reported, and Zhong et al. determinated the regulatory role of circTCF25-miR-103a-3p/miR-107-CDK6 axes in bladder cancer [28]. Another study also found that cir-ITCH is involved in the regulation of the Wnt/β-catenin signaling pathway in vivo, as sponge of miR-7, miR-17, miR-20a, and miR-214 [27, 36].

CircRNA-binding proteins

It has been reported that RNA-binding proteins (RBPs), such as RNA polymerase II [8], Argonaute [3], and MBL [50], can bind to circRNAs. In addition, several studies showed that circRNAs may play a role in the genesis and development of tumor via binding key proteins associated with cell proliferation, metastasis, and apoptosis. Wu et al. demonstrated that ectopic expression of the circular RNA circ-Foxo3 repressed cell cycle progression through binding to the cell cycle proteins cyclin-dependent kinase 2 (CDK2) and cyclin-dependent kinase inhibitor 1 (or p21), resulting in the formation of a ternary complex. CDK2 interacts with cyclin A and cyclin E to facilitate cell cycle entry, while p21 inhibits these interactions and arrests cell cycle progression [51]. Thus, the formation of circ-Foxo3-p21-CDK2 ternary complex can inhabit the function of CDK2 and block cell cycle progression. Because CDK2 is involved in a variety of cancers, such as breast cancer [52], NSCLC [53], and CRC [54], it is conceivable that circ-Foxo3 takes a part in cancers above by formation of circ-Foxo3-p21-CDK2 ternary complex. Circ-Foxo3 can also bind to proteins ID1, E2F1, FAK, and HIF-1α (HIF1A), retaining them in the cytoplasm and promoting cardiac senescence [55]. These findings above indicate that circRNAs may function as decoys that modify the cellular destination and/or function of bound partners.

CircRNAs and DNA

DNA replication is the process of producing two identical replicas from one original DNA molecule. During DNA replication, circRNAs enriched in the nucleus may interact with the opposite strand of its genomic DNA through base-pairing and thus form a DNA-RNA triple helix affecting DNA replication. It is reported that pRNA interacts with the target site of the transcription factor TTF-I, forming a DNA-RNA triplex, which simultaneously recruits DNMT3b to repress rRNA expression [56]. Also, lncRNA ANRASSF1 interacts with a DNA-forming RNA/DNA hybrid at the transcription start site, leading to reduced transcription of RAS-association domain family member 1A (RASSF1A) [57]. These examples highlight that the interactions between DNA and nucleus-residing circRNAs in a manner akin to linear ncRNAs.

Conclusions

It has been decades since circRNAs were discovered. Though previously thought to be errors in RNA splicing, circRNAs now have drawn increasing attention of scientists because of recent improvement of high-throughput sequencing technologies and bioinformatics progression. In this review, we regarded natural circRNAs as an abundant, stable, diverse, and conserved class of RNA molecules. Based on the location concerning the nearest protein-coding gene, circRNAs can be classified into three subclasses: exonic circRNAs, ciRNAs, and ElciRNAs. According to their functions, circRNAs can be categorized as sponge, translation, biomarker, and regulation molecules. Their roles made them potential biomarkers of diagnosis and prognosis and therapeutical targets.

Perspective

Recent advances about circRNAs have been focused on their biogenesis and functions as miRNA sponges. Though there has been much progress in circRNAs, the field of their functions, related mechanisms, and degradation need to be more investigated. Actually, the field of circRNAs remains largely unexplored, such as developmental stage-specific expression, turnover, localization, and degradation. Compared with miRNA and long noncoding RNAs (lncRNAs), circRNAs are promising clinical diagnostic and prognostic markers for their stable structure. Among the three subclasses of circular RNAs, one is cytoplasmatic (circRNA) and two are located in the nucleus (ciRNAs and EIciRNA) [35, 8], suggesting that circular RNAs may have a multitude of epigenetic roles in the cell.

CircRNAs were considered untranslatable, but recent studies prove that most circRNAs carry open reading frames, and some of them have IRES elements. With emerging evidence, more researchers are interested in this function of circRNAs. Predictably, this will become the new frontier in research of circRNAs.

Recent report shows for the first time the presence of abundant circRNAs in exosomes [6]. Exosomes are small membrane vesicles of endocytic origin secreted by most cell types [58]. The sorting of circRNAs to exosomes may be regulated by changes of associated miRNA levels in producer cells and may transfer biological activity to recipient cells. Undoubtedly, circRNAs have the potential to become clinical diagnostic and prognostic markers, and results above lay the foundation for development of circRNAs as a new class of exosome-based cancer biomarkers and suggest the potential biological function of exosomal circRNAs.

With the development of technology and research, further studies will reveal the functions of the vast majority of circRNAs in physiological and pathological processes. Furthermore, circRNAs will play a crucial role in the diagnosis and treatment of cancer.

Abbreviations

A3SS: 

Alternative 3′ splicing site

A5SS: 

Alternative 5′ splicing site

ADAR: 

Enzyme adenosine deaminase acting on RNA

AGO: 

Argonaute

APL: 

Acute promyelocytic leukemia

AS: 

Alternative splicing events

CDK2: 

Cyclin-dependent kinase

CDK6: 

Cyclin-dependent kinase 6

CDR1as: 

Antisense to the cerebellar degeneration-related protein1 transcript

ceRNAs: 

Competing endogenous RNAs

circRNAs: 

Circular RNAs

ciRNA: 

Circular intronic RNA

ciRS-7: 

Circular RNA sponge for miR-7

CRC: 

Colorectal cancer

cSCC: 

Cutaneous squamous cell carcinoma

EGFR: 

Epidermal growth factor receptor

ElciRNA: 

Exon-intron circular RNA

EMT: 

Mesenchymal transition

ES: 

Exon skipping

ESCC: 

Esophageal squamous cell carcinoma

EVs: 

Extracellular vesicle

exo-circRNAs: 

Exosomal circRNAs

f-circRNA: 

Fusion circRNAs

HCC: 

Hepatocellular carcinoma

IR: 

Intron retention

IRES: 

Internal ribosomal entry sites

IRS-1: 

Insulin receptor substrate-1

lncRNA: 

Long noncoding RNA

LSCC: 

Laryngeal squamous cell cancer

miRNA: 

MicroRNA

MREs: 

MiRNA response elements

mTOR: 

Mammalian target of rapamycin

ncRNA: 

Noncoding RNAs

NSCLC: 

Non-small cell lung cancer

Pak1: 

P21-activated kinase-1

PDAC: 

Pancreatic ductal adenocarcinoma

PIK3CD: 

Phosphoinositide 3-kinase catalytic subunit delta

Pol II: 

RNA polymerase II

QKI: 

RNA-binding quaking

RASSF1A: 

RAS-association domain family member 1A

RBP: 

RNA-binding protein

rRNA: 

Ribosomal RNA

snRNA: 

Small nuclear RNA

TNM: 

Tumor node metastasis

U1 snRNP: 

U1 small nuclear ribonucleoprotein particle

Declarations

Acknowledgements

We thank Dr. Bin Shan for the helpful discussion.

Funding

This work was supported by grants from the National Natural Scientific Foundation of China (Nos. 81171841, 81200366, 81372515, and 81572281).

Availability of data and materials

Not applicable.

Authors’ contributions

All authors have contributed to the preparation of this manuscript. All authors have read and approved the manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Institute of Medical Sciences, Xiangya Hospital, Central South University
(2)
Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya Hospital, Central South University
(3)
Department of Thoracic Surgery, Xiangya Hospital, Central South University

References

  1. Nigro JM, Cho KR, Fearon ER. Scrambled exons. Cell. 1991;64:607–13.View ArticlePubMedGoogle Scholar
  2. Cocquerelle C, Mascrez B, Hetuin D. Mis-splicing yields circular RNA molecules. Faseb J. 1993;7:155–60.PubMedGoogle Scholar
  3. Memczak S, Jens M, Elefsinioti A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495:333–8.View ArticlePubMedGoogle Scholar
  4. Jeck WR, Sorrentino JA, Wang K, Slevin MK, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA. 2013;19:141–57.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Wang Z. Not just a sponge: new functions of circular RNAs discovered. Sci China Life Sci. 2015;58:407–8.View ArticlePubMedGoogle Scholar
  6. Li Y, Zheng Q, Bao C, et al. Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. Cell Res. 2015;25:981–4.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Zhang XO, Dong R, Zhang Y, et al. Diverse alternative back-splicing and alternative splicing landscape of circular RNAs. Genome Res. 2016;26:1277–87.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Zhang Y, Zhang XO, Chen T, et al. Circular intronic long noncoding RNAs. Mol Cell. 2013;51:792–806.View ArticlePubMedGoogle Scholar
  9. Salzman J, Chen RE, Olsen MN, et al. Cell-type specific features of circular RNA expression. PLoS Genetics. 2013;9:119–29.View ArticleGoogle Scholar
  10. Ivanov A, Memczak S, Wyler E, et al. Analysis of intron sequences reveals hallmarks of circular RNA biogenesis in animals. Cell Rep. 2015;10:170–7.View ArticlePubMedGoogle Scholar
  11. Conn SJ, Pillman KA, Toubia J, et al. The RNA binding protein quaking regulates formation of circRNAs. Cell. 2015;160:1125–34.View ArticlePubMedGoogle Scholar
  12. Gao Y, Wang J, Zheng Y, Zhang J, Chen S, Zhao F. Comprehensive identification of internal structure and alternative splicing events in circular RNAs. Nat Commun. 2016;7:12060.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.View ArticlePubMedGoogle Scholar
  14. Hansen TB, Jensen TI, Clausen BH, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495:384–8.View ArticlePubMedGoogle Scholar
  15. Li Z, Huang C, Bao C, et al. Exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol. 2015;22:256–64.View ArticlePubMedGoogle Scholar
  16. Perriman R, Ares MJ. Circular mRNA can direct translation of extremely long repeating-sequence proteins in vivo. RNA. 1998;4:1047–54.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Abouhaidar MG, Venkataraman S, Golshani A, Liu B, Ahmad T. Novel coding, translation, and gene expression of a replicating covalently closed circular RNA of 220 nt. Proc Natl Acad Sci USA. 2014;111:14542–7.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Chen CY, Sarnow P. Initiation of protein synthesis by the eukaryotic translational apparatus on circular RNAs. Science. 1995;268:415–17.View ArticlePubMedGoogle Scholar
  19. Chen XP, Han P, Zhou T, et al. circRNADb: a comprehensive database for human circular RNAs with protein-coding annotations. Sci Rep. 2016;6:34985.Google Scholar
  20. Jeck WR, Sharpless NE. Detecting and characterizing circular RNAs. Nat Biotechnol. 2014;32:453–61.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Lasda E, Parker R. Circular RNAs co-precipitate with extracellular vesicles: a possible mechanism for circRNA clearance. PLoS One. 2016;11:e148407.View ArticleGoogle Scholar
  22. Memczak S, Papavasileiou P, Peters O, et al. Identification and characterization of circular RNAs as a new class of putative biomarkers in human blood. PLoS One. 2015;10:e0141214.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Li P, Chen S, Chen H, et al. Using circular RNA as a novel type of biomarker in the screening of gastric cancer. Clin Chim Acta. 2015;444:132–6.View ArticlePubMedGoogle Scholar
  24. Wang X, Zhang Y, Huang L, et al. Decreased expression of hsa_circ_001988 in colorectal cancer and its clinical significances. Int J Clin Exp Pathol. 2015;8:16020–5.PubMedPubMed CentralGoogle Scholar
  25. Huang G, Zhu H, Shi Y, et al. Cir-ITCH plays an inhibitory role in colorectal cancer by regulating the Wnt/β-catenin pathway. PLoS One. 2015;10:e131225.Google Scholar
  26. Qin M, Liu G, Huo X, et al. Hsa_circ_0001649: a circular RNA and potential novel biomarker for hepatocellular carcinoma. Cancer Biomark. 2016;16:161–9.View ArticlePubMedGoogle Scholar
  27. Xuan L, Qu L, Zhou H, Wang P, et al. Circular RNA: a novel biomarker for progressive laryngeal cancer. Am J Transl Res. 2016;8:932–9. Original Article.PubMedPubMed CentralGoogle Scholar
  28. Zhong Z, Lv M, Chen J. Screening differential circular RNA expression profiles reveals the regulatory role of circTCF25-miR-103a-3p/miR-CDK6 path way in bladder carcinoma. Sci Rep-UK. 2016;6:30919.View ArticleGoogle Scholar
  29. Guarnerio J, Bezzi M, Jeong JC, et al. Oncogenic role of fusion-circRNAs derived from cancer-associated chromosomal translocations. Cell. 2016;165:289–302.View ArticlePubMedGoogle Scholar
  30. Alhasan AA, Izuogu OG, Al-Balool HH, et al. Circular RNA enrichment in platelets is a signature of transcriptome degradation. Blood. 2016;127:E1–E11.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Best MG, Sol N, Kooi I, et al. RNA-seq of tumor-educated platelets enables blood-based pan-cancer, multiclass and molecular pathway cancer diagnostics. Cancer Cell. 2015;28:666–76.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Sand M, Bechara F G, Gambichler T, et al. Circular RNA expression in cutaneous squamous cell carcinoma. J Dermatol Sci. 2016;83:210–8.Google Scholar
  33. Qu S, Song W, Yang X, et al. Microarray expression profile of circular RNAs in human pancreatic ductal adenocarcinoma. Genomics Data. 2015;5:385–7.View ArticlePubMedPubMed CentralGoogle Scholar
  34. Li F, Zhang L, Li W, Deng J, Zheng J, et al. Circular RNA ITCH has inhibitory effect on ESCC by suppressing the Wnt/beta-catenin pathway. Oncotarget. 2015;6:6001–13.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Giles KM, et al. miRNA-7-5p inhibits melanoma cell migration and invasion. Biochem Biophys Res Commun. 2013;430:706–10.View ArticlePubMedGoogle Scholar
  36. Wu D, et al. MicroRNA-7 regulates glioblastoma cell invasion via targeting focal adhesion kinase expression. Chin Med J. 2011;124:2616–21.PubMedGoogle Scholar
  37. Wang W, et al. Regulation of epidermal growth factor receptor signaling by plasmid-based MicroRNA-7 inhibits human malignant gliomas growth and metastasis in vivo. Neoplasma. 2013;60:274–83.View ArticlePubMedGoogle Scholar
  38. Zhao X, et al. MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor. Oncogene. 2013;32:1363–72.View ArticlePubMedGoogle Scholar
  39. Fang Y, et al. MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma. Hepatology. 2012;55:1852–62.View ArticlePubMedGoogle Scholar
  40. Xiong S, Zheng Y, Jiang P, et al. MicroRNA-7 inhibits the growth of human non-small cell lung cancer A549 cells through targeting BCL-2. Int J Biol Sci. 2011;7:805–14.View ArticlePubMedPubMed CentralGoogle Scholar
  41. Shi X, Sun M, Liu H, Yao Y, Song Y. Long non-coding RNAs: a new frontier in the study of human diseases. Cancer Lett. 2013;339:159–66.View ArticlePubMedGoogle Scholar
  42. Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med. 2009;60:167–79.View ArticlePubMedGoogle Scholar
  43. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–69.View ArticlePubMedGoogle Scholar
  44. Dropcho EJ, Chen YT, Posner JB, Old LJ. Cloning of a brain protein identified by autoantibodies from a patient with paraneoplastic cerebellar degeneration. Proc Natl Acad Sci USA. 1987;84:4552–56.View ArticlePubMedPubMed CentralGoogle Scholar
  45. Xu H, Guo S, Li W, et al. The circular RNA Cdr1as, via miR-7 and its targets, regulates insulin transcription and secretion in islet cells. Sci Rep-UK. 2015;5:12453.View ArticleGoogle Scholar
  46. Kefas B, et al. microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res. 2008;68:3566–72.View ArticlePubMedGoogle Scholar
  47. Reddy SDN, et al. MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions. Cancer Res. 2008;68:8195–200.View ArticlePubMedPubMed CentralGoogle Scholar
  48. Webster RJ, Giles KM, Price KJ, et al. Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem. 2009;284:5731–41.View ArticlePubMedGoogle Scholar
  49. Saydam O, Senol O, Wurdinger T, et al. miRNA-7 attenuation in schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathways. Cancer Res. 2011;71:852–61.View ArticlePubMedGoogle Scholar
  50. Ashwal-Fluss R, Meyer M, Pamudurti NR, Ivanov A, Bartok O, Hanan M, Evantal N, Memczak S, Rajewsky N, Kadener S. circRNA biogenesis competes with pre-mRNA splicing. Mol Cell. 2014;56:55–66.View ArticlePubMedGoogle Scholar
  51. Du W, Yang W, Liu E, et al. Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK2. Nucleic Acids Res. 2016;44:2846–58.View ArticlePubMedPubMed CentralGoogle Scholar
  52. Scott GK, Chu D, Kaur R, et al. ERpS294 is a biomarker of ligand or mutational ERα activation and a breast cancer target for CDK2 inhibition. Oncotarget. 2016;12735.Google Scholar
  53. Cai F, Zhu Q, Miao Y, et al. Desmoglein-2 is overexpressed in non-small cell lung cancer tissues and its knockdown suppresses NSCLC growth by regulation of p27 and CDK2. J Cancer Res Clin Oncol. 2016;1–11.Google Scholar
  54. Beale G, Haagensen EJ, Thomas HD, et al. Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer. Br J Cancer. 2016;115:682–90.Google Scholar
  55. Du W, Yang W, Chen Y, Wu Z, Foster FS, Yang Z, Li X, Yang B. Foxo3 circular RNA promotes cardiac senescence by modulating multiple factors associated with stress and senescence responses. Eur Heart J. 2016;ehw001.Google Scholar
  56. Schmitz KM, Mayer C, Postepska A, Grummt I. Interaction of noncoding RNA with the rDNA promoter mediates recruitment of DNMT3b and silencing of rRNA genes. Genes Dev. 2010;24:2264–9.View ArticlePubMedPubMed CentralGoogle Scholar
  57. Beckedorff FC, Ayupe AC, Crocci-Souza R, Amaral MS, Nakaya HI, Soltys DT, Menck CF, Reis EM, Verjovski-Almeida S. The intronic long noncoding RNA ANRASSF1 recruits PRC2 to the RASSF1A promoter, reducing the expression of RASSF1A and increasing cell proliferation. PLoS Genet. 2013;9:e1003705.View ArticlePubMedPubMed CentralGoogle Scholar
  58. Sonia AM, Linda BL, Christoph K, et al. Glypican1 identifies cancer exosomes and facilitates early detection of cancer. Nature. 2015;523:177–82.View ArticleGoogle Scholar

Copyright

© The Author(s). 2017